Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemoradiotherapy for Gastric Cancer
NCT00123318Phase 3Completed
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Feb 2003
- Primary completion
- Feb 2012
- Modality
- Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of epirubicin, Cisplatin micelle injection (HA132) and fluorouracil in gastric cancer (GC), sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoints: Percentage of patients who develop grade 3 or grade 4 haematological and gastrointestinal acute toxicity at 3 years, Percentage of patients who complete the planned chemoradiation protocol at 3 years and 1 more. Started Feb 2003; status: completed.
02
Drugs
epirubicinCisplatin micelle injection (HA132)fluorouracil
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00123318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123318.